Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TC-110 T Cells · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 | EXPERIMENTAL | The Phase 1 portion of the study will proceed according to a standard 3 + 3 dose escalation schema. Patients will be enrolled into 3 cohorts based on disease: NHL cohort, low tumor burden ALL cohort, and high tumor burden ALL cohort. |
| Phase 2 | EXPERIMENTAL | The phase 2 portion of the study will evaluate the efficacy of TC-110 T cells administered at the RP2D, preceded by a lymphodepleting regimen. |
| Name | Type | Description |
|---|---|---|
| TC-110 T Cells | DRUG | TC-110 T Cells |
| Fludarabine | DRUG | Flu/Cy Lymphodepletion |
| Cyclophosphamide | DRUG | Flu/Cy Lymphodepletion |
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed * Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU * Histologically c...
TC-110 T Cells is an investigational cell therapy being studied for the treatment of relapsed or refractory non-Hodgkin lymphoma, including diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma, and follicular lymphoma, as well as acute lymphoblastic leukemia. It is in Phase 1 clinical development.
TC-110 T Cells is being developed by Adaptimmune Therapeutics PLC, a biopharmaceutical company traded on the NASDAQ under the ticker ADAP. The company is conducting clinical research on this investigational therapy for hematologic malignancies.
TC-110 T Cells is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 1 clinical trial has been completed to evaluate its safety and preliminary efficacy in patients with relapsed or refractory blood cancers.
TC-110 T Cells was studied in a Phase 1 clinical trial registered as NCT04323657, titled 'TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia.' The trial enrolled 6 participants in the United States and has been completed. The study included patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia.
TC-110 T Cells is a cell therapy that uses modified T cells to target cancer cells. The specific molecular target of TC-110 T Cells has not been disclosed in the available information. The therapy is being evaluated for its ability to treat relapsed or refractory hematologic malignancies.
TC-110 T Cells is a distinct investigational cell therapy. No alternative names for this product have been identified in the available information. It is being developed under the name TC-110 T Cells by Adaptimmune Therapeutics.